Business Daily.
.
A+ R A-

Alector Raises $32 Million Series C to Advance Immuno-Modulation Approach for Neurodegenerative Diseases

E-mail Print PDF
SAN FRANCISCO--(BUSINESS WIRE)--Alector, a biotech company pioneering the discovery and development of immuno-modulatory therapies for neurodegenerative disorders, announced today that it has raised $32M in Series C financing.

imageimage
Grow Your Business with Times Media
Business Daily Media